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Abstract
Background: Prion diseases are characterized by the accumulation in the central nervous system of an abnormally
folded isoform of the prion protein, named PrPSc. Aggregation of PrPSc into oligomers and fibrils is critically involved
in the pathogenesis of prion diseases. Oligomers are supposed to be the key neurotoxic agents in prion disease, so
modulation of prion aggregation pathways with small molecules can be a valuable strategy for studying prion
pathogenicity and for developing new diagnostic and therapeutic approaches. We previously identified thienyl
pyrimidine compounds that induce SDS-resistant PrPSc (rSDS-PrPSc) oligomers in prion-infected samples.
Results: Due to the low effective doses of the thienyl pyrimidine hits, we synthesized a quaterthiophene-bis-triazine
compound, called MR100 to better evaluate their diagnostic and therapeutic potentials. This molecule exhibits a
powerful activity inducing rSDS-PrPSc oligomers at nanomolar concentrations in prion-infected cells. Fluorescence
interaction studies of MR100 with mouse PrP fibrils showed substantial modification of the spectrum, and the interaction
was confirmed in vitro by production of rSDS-oligomer species upon incubation of MR100 with fibrils in SDS-PAGE gel.
We further explored whether MR100 compound has a potential to be used in the diagnosis of prion diseases. Our
results showed that: (i) MR100 can detect rSDS-oligomers in prion-infected brain homogenates of various species,
including human samples from CJD patients; (ii) A protocol, called “Rapid Centrifugation Assay” (RCA), was developed
based on MR100 property of inducing rSDS-PrPSc oligomers only in prion-infected samples, and avoiding the protease
digestion step. RCA allows the detection of both PK-sensitive and PK-resistant PrPSc species in rodents samples but also
from patients with different CJD forms (sporadic and new variant); (iii) A correlation could be established between the
amount of rSDS-PrPSc oligomers revealed by MR100 and the duration of the symptomatic phase of the disease in CJD
patients; and (iv) Bioassay experiments showed that MR100 can trap prion infectivity more efficiently than P30 drug.
Conclusions: MR100 is a powerful tool not only for studying the prion aggregation pathways regarding oligomeric and
sPrPSc species, but also for developing alternative methods for the detection of prion-infected samples. Considering our
bioassay results, MR100 is a promising molecule for the development of prion decontamination approaches.
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Background
Prions are unconventional infectious agents responsible for
fatal neurodegenerative disorders in animals and humans
[1]. In humans, prion diseases are mostly represented by
Creutzfeldt-Jakob disease (CJD) which is classified into
three groups: sporadic (85 % of cases), genetic (10-15 %)
and acquired (less than 5 %) [2]. The disease is character-
ized by abnormal prion protein (PrPSc) deposits in the
brain of CJD patients, often forming large amyloid plaques
and fibrils. The crucial step in the transmission and mani-
festation of prion diseases is the conversion of benign
monomeric cellular prion proteins (PrPC) into pathogenic
multimeric PrPSc isoforms [3, 4]. Structural differences
confer specific biochemical properties: PrPC is detergent-
soluble and completely digested by proteinase K (PK),
whereas PrPSc is detergent-insoluble, tends to oligomerize
to form fibrils and is partially resistant to PK. PrPSc diges-
tion by PK produces a trimmed C-terminal fragment,
called PrP(27-30) or PK-resistant PrPSc (rPrPSc), and is
considered to be the main biomarker of prion disease. The
proteinase K digestion assay performed on brain tissue is
the referenced method used for the diagnosis of human
prion diseases. However, a growing number of evidences
shows that: (i) A novel prion disease described by
Gambetti in 2008, demonstrated that 2-3 % of CJD cases
are characterized by a prion protein highly sensitive to
proteinase K digestion and difficult to detect in classical
conditions. In the absence of PK-resistant marker (because
those cases do not have mutations in the PRNP gene) they
can be easily missed as prion cases [5–8]; (ii) PK-sensitive
PrPSc fraction (sPrPSc) represents more than 80 % of the
total PrPSc isoforms, thus it could be interesting to find
methods targeting these species to better understand their
role [9–12]; and (iii) the crucial role of oligomeric species
recognized as the most toxic forms, not only in prion
diseases but also for most prionopathies, whereas amyloid
fibrils have a role in sequestering dangerous soluble oligo-
mers should be taken into account when searching for anti-
amyloid drugs [13–15]. Altogether, these studies underline
the necessity of finding new tools to study the various PrPSc
species and their role in prion pathogenicity for developing
new diagnostic and therapeutic strategies. Recently, by
using virtual and cellular drug screenings, we identified a
family of thienyl pyrimidine drugs (P30 and A6 are the lead
compounds among 50 molecules tested) that allow us to
detect SDS-resistant PrPSc (rSDS-PrPSc) dimers and trimers
after proteinase K digestion [16]. These rSDS-PrPSc oligo-
mers are only observed in prion-infected samples, suggest-
ing a potential use for prion diagnosis. The low affinity of
P30 for the normal PrPC isoform was confirmed by Surface
Plasmon Resonance studies (SPR or Biacore) with a calcu-
lated affinity of 147 ± 50 uM. The binding of P30 for PrPSc
could not be evaluated because of aggregation issues in the
Biacore sensor chip. Other biochemical studies showed
that: (i) P30 did not cross-link recombinant full-length PrP
(recPrP) or fibrils in vitro; (ii) P30 did not modify the
kinetics of conversion of recPrP into amyloid fibrils in a
semi-automated assay; and (iii) The effective doses (ED50:
concentration at which 50 % of rSDS-PrPSc oligomers was
achieved) of P30 and A6 were in the micromolar range,
which is too low to understand their mechanism of action
in vitro. Indeed, it was not possible to decipher if P30:
(i) catalyzes oligomers from PrPSc monomers, or (ii) cross-
links pre-existing small oligomers as dimers and trimers,
or (iii) interacts with larger aggregates such as fibrils, and
under denaturing conditions and migration on SDS-PAGE
gel, rSDS-PrPSc dimers and trimers are observed.
In order to better understand the mechanism of action
of previously identified thienyl pyrimidine compounds
[16], as well as to evaluate their diagnostic and thera-
peutic potentials, we searched for analogs with stronger
activity. Based on the results of a structure-activity study,
we synthesized a quaterthiophene-bis-triazine compound,
called MR100 [17, 18]. Our main results show that: (i)
MR100 exhibits a very powerful rSDS-PrPSc oligomer-
inducing activity at nanomolar concentrations in prion-
infected cells; (ii) fluorescence interaction studies of MR100
with mouse PrP fibrils showed substantial modification of
the spectrum, suggesting the binding of MR100 to PrP fi-
brils; (iii) the in vitro binding was confirmed in SDS-PAGE
gels, showing production of rSDS-oligomer species upon
incubation of MR100 with fibrils, and the rSDS-oligomeric
species were colored orange as is MR100; (iv) MR100 can
detect rSDS-oligomers in prion-infected brain homogenates
of various species; (v) a protocol, called “Rapid Centrifuga-
tion Assay” (RCA), based on MR100 property of inducing
rSDS-PrPSc oligomers only in prion-infected samples, and
avoiding the protease digestion step was developed. RCA
allows the detection of both PK-sensitive and PK-resistant
PrPSc species in prion-infected samples from rodents and
also from patients with different CJD forms (sporadic and
new variant); (vi) a correlation was established between the
amount of rSDS-PrPSc oligomers revealed by MR100
and the duration of the symptomatic phase of the disease
in CJD patients; and (vii) bioassay experiments show that
MR100 can trap prion infectivity more efficiently than
P30 drug, suggesting a potential of MR100 as a surface
prion decontaminant.
Results
Design and synthesis of MR100, a derivative that combines
the chemical characteristics of the thienyl pyrimidine
compounds A6 and A18
We previously identified thienyl pyrimidine compounds
that allow the detection of rSDS-PrPSc dimers and tri-
mers on western blot [16]. A structure-activity study
performed on 23 derivatives of P30 showed that the
activity depended on the presence of a donor group of π
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electrons (NH- or SH-) branched to a conjugated C6 het-
erocycle, such as a pyrimidine or an azine, and of an ac-
ceptor group of π electrons (Br-, Cl-, CN-) branched to a
thienyl cycle (Table 1) [16, 17]. We also found that the
addition of a second thienyl cycle (such as the A6 and
A14 compounds), instead of a halogen atom, accentuated
their electro-attractive character and increased the rSDS-
PrPSc oligomer-inducing activity [17]. We hypothesized
that dimerization of the thienyl pyrimidine scaffold of A6
could enhance delocalization of π electrons and further
increase its rSDS-PrPSc oligomer-inducing activity. We
thus synthesized MR100, a bivalent ligand with a chemical
scaffold that is similar to an A6 dimer and includes the
triazine cycle of A18 (Table 1) [18].
MR100 rSDS-PrPSc oligomer-inducing activity is five
thousand times stronger than that of A6
We then tested whether MR100 and the two synthesis
intermediates MR1 and MR2 could allow the detection
of rSDS-PrPSc dimers and trimers in prion-infected mouse
neuroblastoma N2a58/22 L cells. N2a58/22 L cells were
incubated with 20 μM of each compound or with A6, used
as a positive control, for 4 days. Negative controls were
untreated cells (CTR), or incubated with vehicle (DMSO)
alone. When cells reached confluence, they were lysed,
PK-digested and analyzed by immunoblotting with the
SAF mix of anti-PrP antibodies. MR100 had a strong
rSDS-PrPSc oligomer-inducing activity, whereas only
traces were detected in cells incubated with MR1 and no
rSDS-PrPSc oligomer was visible in samples incubated
with MR2 (Fig. 1a).
Because the MR100 compound seemed to be more po-
tent than A6, we performed dose-response curves using
a range of concentrations (from 0.5 to 2.5 μM) of
MR100, P30 and A6 (Fig. 1b). rSDS-PrPSc oligomers
could not be detected when P30 was used at such low
concentrations because its ED50 was previously esti-
mated at 17 μM. Incubation of N2a58/22 L cells with
2.5 μM A6 (its estimated ED50) [16] induced moderate
rSDS-PrPSc oligomer formation. Conversely, the lowest
tested concentration (0.5 μM) of MR100 was already suf-
ficient to saturate the signal, indicating that MR100 is
more effective than P30 and A6 (Fig. 1b). To determine
the ED50 of MR100, we performed a dose-response
curve in N2a58/22 L cells with MR100 concentrations
ranging from 1 pM (10-12 M) to 10 μM (10-5 M). Oligo-
mers were detected when only 0.1 nM MR100 was used
and the signal was saturated with 1nM MR100, suggest-
ing that MR100 ED50 was between 0.1 and 1 nM
(Fig. 1c). Therefore, we estimated that MR100 is active
at concentrations 5000 times lower than A6 and 30,000
times lower than P30.
MR100 does not oligomerize PrPC in either normal or
prion-infected cells
Since MR100 is more potent than P30 and A6, we
wanted to determine whether the new drug could also
induce the oligomer-induced activity on PrPC isoforms.
To this aim, N2a58 cells corresponding to the parental
non-infected line, were first incubated with 20 μM of
MR100 for 4 days. Western blot analysis of the cell ly-
sates was performed using SAFmix, since it recognizes
Table 1 Chemical structure of thienyl pyrimidine compounds with oligomer-inducing activity and schematic representation of the
synthesis of the new derivative, MR100
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both PrPC and PrPSc isoforms and labels the rSDS-PrPSc
oligomers very strongly. We hypothesized that if rSDS-
PrPC oligomers exist, SAFmix should also recognize
these species. However, western blot analysis did not
show rSDS-PrPC oligomers in N2a58 cells upon treat-
ment with MR100 either before or after PK digestion
a


















MR100CTR DM A6 MR1 MR2
PK +
G3PDH / PK -
37 
Fig. 1 MR100 has a stronger PrPSc oligomer-inducing activity in prion-infected N2a58/22 L cells than P30 and A6. a Effect of the newly synthesized
MR1, MR2 and MR100 compounds in prion-infected N2a58/22 L cells. Cells were left untreated (CTR) or incubated with 20 μM of A6 (positive control),
MR1 and MR2 (synthesis intermediates), MR100, or 20 μL DMSO (DM) for 4 days. Protein lysates were analyzed by immunoblotting with the SAF mix
(a mixture of the anti-PrP SAF60, SAF69 and SAF70 monoclonal antibodies) after proteinase K (PK) digestion. b Comparison of the oligomer-inducing
activity of P30, A6 and MR100. Prion-infected N2a58/22 L cells were incubated with 0.5, 1 or 2.5 μM of each compound, or 20 μL DMSO (DM) for 4 days.
Protein lysates were then analyzed by immunoblotting with the SAF mix after PK digestion. c MR100 dose-response curve in prion-infected
N2a58/22 L cells. Successive dilutions of MR100 in DMSO were used to obtain final concentrations ranging from 10-12M (1pM) to 10-5M (10 μM). Cells
were incubated for 4 days and at confluence they were lysed. Protein lysates were analyzed by immunoblotting with the SAF mix after PK digestion
according to the previously described protocol [16, 30]. Loading control was performed with antibodies against glyceraldehyde-3-P dehydrogenase
(G3PDH) and before proteinase K digestion. Molecular masses (20–50 kDa) are indicated on the left side of the panels
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(Fig. 2a). We also used SAF32, whose epitope recognizes
the octarepeats (epitopes 59-65) in the N-terminal region
of the protein, since normal cells have a higher proportion
of full-length PrPC protein than truncated protein. We did
not observe any rSDS-PrPC oligomers using SAF32 in non-
infected cells treated with a range of MR100 concentration
(Fig. 2b). These results are in accordance with our previous
data using P30 and A6 [16].
Our second hypothesis was that MR100 oligomerizes
PrPC, via PrPSc in prion-infected N2a58/22 L samples.
PK +PK -
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Fig. 2 MR100 did not induce SDS resistant PrPC oligomers. a Parental non-infected cells, N2a58, were left untreated (CTR) or incubated with
20 μM of MR100 or 20 μL DMSO (DM) for 4 days. Protein lysates were analyzed by immunoblotting with the SAF mix before or after PK digestion.
b N2a58 cell lines were left untreated (CTR) or incubated with various concentration of MR100 from 5 to 40 μM or 40 μL of DMSO (DM) for 4 days.
Protein lysates were analyzed by immunoblotting with the SAF 32 before or after PK digestion. Loading control was performed with antibodies
against β actin and before proteinase K digestion. c Schematic representation of the protocols used to test if PrPC isoforms are part of rSDS-oligomers
(Left panel). First step, N2a58/22 L lysates were incubated with 20 μM of MR100 or with proteinase K to eliminate PrPC, then in the second
step, MR100-exposed lysates were digested with proteinase K, while proteinase K digested samples were incubated with MR100. PrPSc species
were then analyzed by western blotting. Western blot analysis of the samples processed according to the two different protocols using the
SAFmix of anti-PrP antibodies (Right panel). CTR, untreated samples, digested by proteinase K; DM, DMSO. Molecular masses (20–50 kDa) are
indicated on the left side of the panels
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Indeed, MR100 could play the role of catalyst for the
conversion of PrPC to PrPSc, as a template for the fold-
ing of PrPC, leading to subsequent oligomerization. To
decipher this, we performed 2 experiments in parallel on
freshly made prion-infected cellular lysates. First, prion-
infected cell lysates were either treated with MR100 (or
DMSO as a negative control) or with PK, after which the
samples previously treated with MR100 or DMSO were
PK-digested, and those previously PK-digested were
treated with MR100 or DMSO (see schema Fig. 2c). We
expected that, if PrPC is implicated in the process of
oligomerization, the samples that were first PK treated in
order to remove PrPC would have fewer oligomers than
samples incubated first with MR100. This was not the
case: samples that were first digested with PK to remove
PrPC before the incubation with MR100 did not exhibit
fewer oligomers than samples incubated first with MR100
and then PK digested as shown in the western blot
(Fig. 2c). This result suggests that PrPC is not implicated
in the process of oligomerization.
Fluorescent studies showed that MR100 interacts with
recPrP proteins
Interaction studies were performed to check whether
the MR100 compound binds to prion protein. We used
purified recombinant full-length mouse prion protein
MoPrP(23-230) folded into α-helices or fibrils to perform
Surface Plasmon Resonance (SPR or Biacore) studies, as
previously performed for P30 and A6 compounds [16].
Unfortunately, the experimental conditions to measure
the interaction between MR100 and MoPrP(23-230) failed
because we had to dilute the MR100 in buffer conditions
that render it too insoluble to determine affinity measure-
ments. Since MR100 was an orange-colored compound
containing several heterocycles, such as thienyl and azine,
some potential fluorescence properties could be used for
interaction studies. Absorption spectra were recorded for
MR100 from 200-600 nm and the maximal absorption
wavelength of the compound was detected at 470 nm and
was thus selected for excitation of the molecule with a
fluorimeter. After excitation of the MR100 compound at
470 nm, the maximal emission wavelength of fluorescence
was recorded at 531 nm. We took advantage of these
physical properties to perform interaction studies between
MR100 and recombinant PrP proteins, by following the
fluorescence of MR100 in presence or in absence of
MoPrP(23-230) after 2 h of incubation. Emission spectra
were recorded at an excitation wavelength of 470 nm and
showed that, in presence of the soluble MoPrP(23-230),
the maximal fluorescence signal at 452 nm is doubled
compared to control MR100 alone (Fig. 3a). For PrP
fibrils, we also observed an increase of the fluorescence
signal but also a strong red-shift of the emission spectrum:
the maximal wavelength shifted from 452 nm to 460 nm,
and a large shoulder appeared around 500 nm (Fig. 3a).
These results illustrated significant modifications in the
environment of the MR100 compound in presence of PrP
proteins and showed that MR100 molecules interact with
both isoforms of MoPrP(23-230). The strong red-shift
observed for the PrP fibrils may be explained by a specific
interaction of MR100 with the quaternary structural ele-
ments of the fibrils. As a control, we followed the fluores-
cence of the aromatic residues (Tyr, Trp) of soluble
MoPrP(23-230) at 295 nm, before the incubation with the
solvent (DMSO) or MR100 compound and after 2 h of
incubation. For MoPrP(23-230) incubated with DMSO,
spectra recorded before addition of the solvent and after
2 h of incubation are very similar indicating that the
solvent did not significantly modify the fluorescence
properties of the protein (Fig. 3b). However, when
MoPrP(23-230) is incubated with MR100, the spectra
recorded before addition of MR100 and after 2 h of
incubation with the molecules are substantially different
(Fig. 3c) as we observed a decrease of the protein fluores-
cence signal by 50 % and a blue-shift of the maximal wave-
length by 9 nm. Upon binding with MR100, a quenching
of the fluorescence of the aromatic residues of the recPrP
is observed due to a more hydrophobic environment that
is also illustrated by a blue-shift from 355 to 346 nm. These
results indicate that the environment of the aromatic resi-
dues of the prion protein is modified in presence of
MR100 and confirm the binding between MR100 and
MoPrP(23-230) previously observed by MR100 fluores-
cence. Alternatively, we performed a fluorescence binding
experiments using Hamster S- or R-fibrils, produced by
different agitation modes (shaking or rotated) and display-
ing distinctive morphologies (R-fibrils are curved, S-fibrils
are straight) linked to different folding patterns of cross–β
structures [19, 20]. Our objective was to see whether
MR100 could preferentially bind to Hamster S- or R-
fibrils. Using the fluorescent property of MR100 as a tracer,
we showed that MR100 interacts with both types of fibrils
although the intensity of the fluorescence is higher
with R-fibrils than S-fibrils (data not shown). After
2 h of incubation in DMSO, P30, A6 or MR100, with
hamster S- or R-fibrils, each mixture was loaded on a
SDS-PAGE gel to directly visualize binding by inducing
more rSDS-oligomers. Upon incubation of hamster fibrils
with MR100 compound we could see an increase of
rSDS-dimers and trimers for both S- and R-fibrils com-
pared to controls incubated with DMSO (Fig. 3d). Re-
markably, for hamster R-fibrils, the bands corresponding
to rSDS-dimers and trimers appeared orange, as did the
MR100 compound, indicating a direct interaction between
MR100 and PrP. We could not directly visualize the
interaction between P30 and A6 compound likely because
the affinity of P30 and A6 compounds for PrP is lower, as
suggested by their ED50.
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MR100 allows rSDS-PrPSc oligomer detection in brain
homogenates infected by different rodent strains
We previously showed that P30 can induce rSDS-PrPSc
oligomers in brain homogenates of mice infected with
the scrapie strain 22 L, but not in non-infected samples
[16]. To assess whether MR100 also had this activity in
vitro, freshly homogenized 22 L-infected mouse or
263 K-infected hamster brain homogenates were incu-
bated with 1 mM MR100 at room temperature for 1 h,
then PK-digested and the reaction stopped by addition
of a protease inhibitor cocktail. Negative controls were
untreated samples (CTR), or 22 L- or 263 K-infected ro-
dent brain homogenates incubated with DMSO alone
(DM). Immunoblotting with the SAFmix showed a
strong signal of rSDS-PrPSc dimers and trimers mostly
in the samples incubated with MR100 (Fig. 4a), suggest-
ing that the MR100 mechanism of action is similar to
that of P30 and A6. The oligomer signal observed with
DMSO after proteinase K digestion is much lower than
the one observed in brain homogenates incubated with
the MR100 compound (Fig. 4a). To assess the extent of
proteinase K resistance of these rSDS-PrPSc species, a
western blot of 22 L-infected brain homogenate incu-
bated with DMSO, P30 or MR100, was made before and
after proteinase K digestion. The results clearly showed
the presence of many more oligomers before PK than
after PK+, for all conditions (DMSO, P30 and MR100),
illustrating that these oligomers are indeed PK sensitive.
The DMSO control also reveals the presence of low
amounts of SDS-resistant oligomers before PK that are
not resistant to the digestion by PK, as shown in Fig. 4b.
In addition, we noticed that when brain homogenates
are treated with 1 mM of either P30 or MR100, the

















































Fig. 3 Fluorescence interaction studies between MR100 and PrP. a Fluorescence studies of MR100 compound incubated with purified recombinant
MoPrP(23-230) proteins. 4 μM of MoPrP(23-230), either soluble or fibrillar, were incubated with 50 μM of MR100 in 1 % DMSO, 50 mM MES
buffer pH6, during 2 h at 25 °C. Emission spectra between 400 and 550 nm were recorded by exciting at 470 nm: 50 μM of MR100 (black),
50 μM of MR100 + α-soluble MoPrP(23-230) (red), 50 μM of MR100 + fibrils of MoPrP(23-230) (green). b-c Fluorescence of tryptophan and
tyrosine residues of soluble MoPrP(23-230) alone (black), or incubated with 1 % DMSO, 50 mM MES buffer pH6, during 2 h at 37 °C (red) (b).
Fluorescence of tryptophan and tyrosine residues of soluble MoPrP(23-230) alone (black), or incubated with 50 μM of MR100 in 1 % DMSO,
50 mM MES buffer pH 6, during 2 h at 37 °C (red) (c). All spectra were recorded at 290 nm. d Hamster-S or -R fibrils at a concentration of
4 μM were incubated with solvent alone (1 % DMSO, 50 mM MES buffer pH6), or 40 μM of P30, A6, or MR100 compounds in 1 % DMSO,
50 mM MES buffer pH6, during 2 h at 25 °C. Samples were then mixed with loading buffer, boiled for 15 min at 90 °C and loaded on a 12 %
SDS-PAGE gel. Proteins in the gel were revealed by silver staining. Molecular weight markers indicated: 27, 42 and 66 kDa. Asterisks showed
dimer and trimer bands that are increased following incubation with MR100 compound
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than for P30, by western blot. This lower signal is likely
due to a strong precipitation effect that we visually
observed with MR100 compound and not with P30.
The “rapid centrifugation assay” allows the detection of
infected samples based on rSDSPrPSc oligomer formation
induced by MR100
To determine whether prions were indeed precipitated
following incubation with high concentrations of MR100,
we developed a new protocol in which, following MR100
incubation, brain homogenates were separated in pellet
and supernatant by quick centrifugation and immediately
analyzed by immunoblotting without PK digestion. We
first observed an orange-colored precipitate in the tube
containing MR100, whereas no pellet was visible for
samples treated with DMSO (Fig. 5a). By using the “rapid
centrifugation assay” (RCA) we evaluated the ability of the
various molecules (DMSO, P30, MR100) to precipitate
PrP isoforms from brain homogenates infected with 22 L
prions. Analyses of supernatants and pellets by western
blot showed that MR100 is necessary to precipitate PrP
isoforms. Indeed, if the RCA is performed with the solvent
alone, precipitation does not occur and the rSDS-PrPSc
oligomers are barely detected (Fig. 5b). Replacement of
MR100 by P30 in the RCA protocol revealed that
MR100 has a strong capacity to concentrate and induce
rSDS-PrPSc oligomers, unlike the P30 compound. We
tested this “rapid centrifugation assay” (RCA) using either
uninfected murine brain homogenates or homogenates
infected with the prion strain 22 L. In prion-infected brain
homogenates, most of the PrP molecules were found in
the pellet, including a substantial fraction of 50-75 kDa
rSDS-PrP oligomers. By contrast, in control, uninfected
brain homogenates (NBH), MR100 precipitated PrPC but
without detection of 50-75 kDa rSDS-PrP oligomers
(Fig. 5c). These results indicate that MR100 oligomerizes
prion-infected brain samples, but not uninfected ones.
This property could be used to develop a new method to
easily discriminate infected and uninfected brain samples
without the PK digestion step, which is replaced by a short
centrifugation step. Suppression of PK digestion could be
an advantage as it allows the detection of all forms of
infectious prions, particularly the sPrPSc forms [5–8]. We
then used the RCA method in hamster brain tissues either
uninfected or infected by the 263 K prion strain, and col-
lected at the terminal stage of the diseases (Fig. 6a). No
rSDS-PrPC oligomers could be detected in normal ham-
ster brain samples by RCA method, whereas rSDS-PrPSc
oligomers were observed in prion-infected homogenates,

























Fig. 4 MR100 shows oligomer-inducing activity in brain homogenates from prion-infected rodents. a MR100 oligomer-inducing activity was
tested using freshly homogenized rodent brain tissues infected with the 22 L (mice) or the 263 K prion strain (hamsters). Fifty μL of 10 % mouse
or hamster brain homogenates were diluted in 300 μL PBS/2 % Sarkosyl, incubated with 1.5 mM MR100 (corresponding to 150 μL of 5 mM
MR100) at room temperature for 1 h or with 150 μL of DMSO as control, and then digested with 20 μg/ml PK at a ratio of 1:50 (PK/proteins).
PK digestion was stopped by addition of a cocktail of protease inhibitors (Complete), before analysis of rPrPSc by western blotting with the SAF
mix according to the previously described protocol [16]. CTR: untreated 22 L- or 263 K-infected brain homogenates (negative control); DM: 22
L- or 263 K-infected brain homogenates incubated with DMSO. b Comparison of P30 and MR100 oligomer-inducing activity on the 22 L prion
strain, before and after proteinase K digestion. Fifty μL of 10 % 22 L-infected brain homogenates were diluted in 350 μL PBS/2 % Sarkosyl, incubated
with 1 mM MR100 or P30 (corresponding to 100 μL of 5 mM MR100 or P30), at room temperature for 1 h. Then, aliquots of 30 μL were taken before
addition of proteinase K, to perform western blot (PK-) probed with SAF mix, but also with anti-β-actin antibodies as loading controls. The rest of the
sample was then digested with 20 μg/ml PK at a ratio of 1:50 (PK/proteins) (PK+). The reaction was stopped by addition of the protease
inhibitor cocktail, before analysis of rPrPSc by western blotting with the SAF mix as in A. DM: 22 L-infected brain homogenates incubated
with 100 μL DMSO. Molecular masses (20–50 kDa) are indicated on the left side of the panels
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We then used the RCA method in hamster brain tissues
collected at various stages of disease (i.e., 109, 130 and
148 days after infection with the 263 K strain) (Fig. 6b). Im-
munoblot analyses after RCA showed the presence of sub-
stantial amounts of rSDS-PrPSc oligomers at day 130 and
148 (terminal stage of disease) and traces at day 109 post-
infection. In order to compare the RCA with the method
that includes the PK digestion step, aliquots of the same
samples were incubated with MR100 for 1 h and then
digested with PK at 37 °C for 1 h (Fig. 6c). In this case, only
small numbers of oligomers were observed at day 148 and
traces at day 130 post-infection, indicating that oligomers
are very sensitive to PK treatment. No signal was detected
at day 109 post-infection, suggesting that at this stage all
PrPSc species are PK-sensitive (Fig. 6b and c). Finally, while
testing the RCA, we noticed that better quality results were
obtained when freshly homogenized brain tissues were
used, possibly because successive freeze-thaw cycles favor
the detection of nonspecific oligomers due to the appear-
ance of protein aggregates.
RCA can differentiate between brain samples from
patients with vCJD and controls
We tested whether RCA was suitable for human prion
strains. Two homogenized brain samples (vCJD3 and
vCJD14) were kindly provided by Dr Cooper (NIBSC,
UK) together with a brain sample from a patient with
sCJD (codon 129 Met/Met; sCJD M/M) and a normal
brain homogenate (NBH, negative control) (Fig. 7). We
first performed western blot analyses before proteinase K
digestion and did not observe rSDS-PrPSc oligomers when
we incubated the samples in presence or absence of the
MR100 drug (Fig. 7a and c). This result suggested that
these rSDS-oligomeric species either do not exist in this
strain, or are too diluted in the original sample to be de-
tectable by western blot. When we applied the RCA proto-
col developed on the rodent strain in the human samples,
we again could not see the rSDS-oligomeric species.
Therefore, we altered the experimental conditions to adapt
the RCA protocol to prion-infected human samples.
Briefly, more concentrated brain homogenates were used,
a
NBH or IBH + MR100
1h incubation at room
Temperature
Precipitation occurs
5 min centrifugation at
8000 g
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Fig. 5 A MR100-based assay can differentiate between prion-infected and normal brain homogenates without proteinase K digestion. a Schematic
description of the RCA protocol to test brain homogenates without PK digestion. Brain tissues were freshly homogenized in microbead-containing
tubes. Normal brain homogenates (NBH) or prion-infected brain homogenates (IBH) were incubated with MR100 for 1 h, at room temperature, leading
to a precipitation of PrP isoforms. After a short centrifugation step, the pellet with MR100 (orange tube) concentrates PrP isoforms, whereas no pellet is
detectable with DMSO. b Comparison of DMSO, P30 and MR100 precipitation capabilities using the RCA protocol. Fifty μL of 10 % 22 L infected brain
homogenates were diluted in 300 μL of PBS/2 % sarcosyl and incubated using either 1.5 mM of P30 or MR100 or an equivalent volume of the solvent
alone (DMSO), at room temperature for 1 h. Then, samples were centrifuged at 8000 g for 5 min. Supernatants (S) were collected and 30 μL of each
supernatant was mixed with an equivalent volume of 2X loading buffer. Pellets (P) were resuspended in 30 μL PBS/2 % Sarcosyl, and mixed with an
equal volume of 2X loading buffer. Thirty microliters of each sample were loaded on 12 % Bis-Tris gels (Criterion, Biorad) and immunoblotting
was carried out with the SAF mix according to standard procedures [16]. The samples (S/P) were analyzed by western blotting using SAF mix
anti-PrP antibodies. c Comparison of infected versus non-infected brain homogenates processed with the RCA protocol. Fifty microliters of
10 % freshly homogenized brain tissues from normal (NBH) or 22 L prion-infected (IBH) mice were processed according to the RCA protocol
described in A and B. Thirty microliters of supernatant (S) or pellet (P) were loaded on 12 % Bis-Tris gels (Criterion, Biorad) and immunoblotting
was carried out with the SAF mix as described above. Molecular masses (20–75 kDa) are indicated on the left side of the panels
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Fig. 6 RCA can detect rSDS-PrPSc oligomers at early stages of the disease. a Fifty microliters of 10 % hamster brain homogenates (NBH or infected
with the 263 K prion strain) were diluted in 300 μL of PBS/2 % Sarkosyl, incubated with 1.5 mM MR100 at room temperature for 1 h and then
centrifuged at 8000 g for 5 min. Supernatants (S) were collected and 30 μL of each supernatant were mixed with an equivalent volume of 2X
loading buffer. Pellets (P) were resuspended in 30 μL PBS/2 % Sarcosyl, and mixed with 30 μL of 2X loading buffer. Thirty microliters of each sample
were loaded on 12 % Bis-tris gels (Criterion, Biorad) and western blotting was carried out with the SAF mix according to standard procedures [16].
Molecular masses (20–75 kDa) are indicated on the left side of the panels. b Hamster brain tissues were collected at various days post-infection (d.p.i.),
as indicated, and freshly homogenized tissues were processed according to the RCA protocol using MR100 and analyzed by immunoblotting as
described above. c To compare the RCA and the PK test, the same hamster brain homogenates (at 109, 130 and 148 d.p.i.) were incubated
with MR100 at room temperature for 1 h, then digested with 20 μg/mL of proteinase K and processed as described in the legend to Fig. 4a.






















































Fig. 7 rSDS-PrPSc oligomers are detected in patients with new variant CJD (vCJD) when tested with RCA. a-b Frozen, homogenized brain samples from
two patients with vCJD, one patient with sCJD (codon 129 M/M genotype) (positive control) and one healthy control (NBH) were from NIBSC. Each
sample was identified by the number attributed by the NIBSC. The RCA assay was carried out as before (see legend to Fig. 5) but adapted to human
samples: 50 μL of 10 % brain homogenates in 100 μL PBS/2 % Sarkosyl were incubated with 2 mM MR100 for 2 h. Before centrifugation, 30 μL was
collected and mixed with 30 μL of 2X loading buffer for immunoblotting analysis (a). The rest of the sample was centrifuged at 11,000 g for 5 min, and
supernatants (S) and pellets (P) were immunoblotted with the SAFmix (b) [16]. c-d For comparison, the same brain homogenates (50 μL of 10 % brain
homogenates in 100 μL PBS/2 % Sarkosyl) were processed with the classical proteinase K digestion assay without MR100. Samples were analyzed before
(c), and after proteinase K digestion (125 μg/mL PK at 37 °C for 1 h) (d). The reaction was stopped by addition of a protease inhibitor cocktail, before
analysis of rPrPSc by western blotting with the SAF mix. Molecular masses (20–75 kDa) are on the left side of the panels
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the MR100 concentration was increased from 1.5 to 2 mM
and the duration of the incubation with MR100 at room
temperature from 1 to 2 h. Western blot analysis probed
with the SAFmix revealed the presence of rSDS-PrPSc olig-
omers in the pellet of all CJD brain homogenates but not
in the NBH sample (Fig. 7b). The centrifugation step com-
bined with a slightly different RCA protocol allowed the
concentration of these rSDS-PrPSc oligomers in the pellet
and their detection by western blot. Thus, it seems that
these species in human brain tissues are not as abundant
as in rodent models because we could not visualize them
prior to PK digestion. Because the marker PrPSc from vCJD
strain has been well described for its lower resistance to
PK digestion we analyzed these brain homogenates by PK
digestion to compare the classical procedure to result
obtained in the RCA (Fig. 7d). Immunoblot analysis
showed the typical presence of rPrPSc in the infected sam-
ples with bands between 19 kDa and 33 kDa. The intensity
of the signal after PK digestion was low, but in accordance




RCA reveals a correlation between the levels of rSDS-PrPSc
oligomers in brain samples from patients with sCJD and
the duration of the symptomatic phase of the disease
We processed ten frozen brain samples from patients with
sCJD (five with the codon 129 Met/Met polymorphism
and five with the codon 129 Val/Val polymorphism) using
the adapted RCA protocol for human tissues. Most of the
infected samples showed the presence of rSDS-PrPSc olig-
omers, but not the NBH control, and the intensity of the
oligomer signal appeared to be proportional to the length
of the clinical phase of the disease (Fig. 8a). Notably, in
one sample sCJD177-06, which came from a patient pre-
senting a short duration of the symptomatic phase of the
disease, the rSDS-PrPSc oligomers were barely detectable.
However, the pattern of precipitated monomers (the level
of PrP monomers in the pellet compared to the amount of
PrP monomers remaining in the supernatant) for the sam-
ple 177-06 is clearly distinguishable from the NBH. For
each sample, we performed a densitometry analysis of the
monomers in the pellet (P) and in the supernatant (S) and
calculated the ratio P/S (see Additional file 1: Table S1).
For normal brain homogenate (NBH) the ratio is 0.5,
meaning that we have 2 times more PrP in the super-
natant than in the pellet, whereas for the sample 177-06,
the ratio is 1.28, meaning that we have more PrPs in the
pellet than in the supernatant. We then normalized these
values by dividing them by the ratio obtained by the non-
infected sample NBH. Thus, for the NBH, the precipita-
tion ratio of monomers is: 1 (0.5/0.5), whereas for 177-06
the value is 2.5 (1.28/0.5). The calculated ratio ranges were
2.2-7.9 for the samples from patients with the Met/Met
polymorphism and 1.8-3.4 for the samples from patients
with the Val/Val polymorphism (Fig. 8b). The ratios of
monomers were all superior to 1 with the samples coming
from sCJD patients. In addition, we noticed that the inten-
sity of the oligomer signal seemed to be proportional to
the length of the clinical phase of the disease, thus we per-
formed a densitometry analysis of the oligomers for each
sample (Fig. 8b). We used Pearson’s test with a probability
of 0.05 (GraphPad software) and confirmed the presence
of a significant correlation between duration of the symp-
tomatic phase of the disease and intensity of the signal
when all the ten sCJD samples were analyzed simultan-
eously (r2 = 0.78, p-value = 0.0007) (Fig. 8c).
Thus, MR100 results allow correlation of the amount
of the rSDS-PrPSc oligomers with the progression of the
pathology in sCJD samples. Altogether, our data suggest
using both criteria, ratio of monomers and densitometry
of rSDS-PrPSc oligomers to discriminate infectious samples
from normal non-infectious samples.
Pre-incubation of prion-infected brain inocula with
MR100 greatly increases animals’ survival
Previous experiments performed with the P30 thienyl
pyrimidine compound showed that it could slightly de-
crease prion infectivity in bioassay experiments and in-
crease survival time (from 154 to 163 days) [16]. As MR100
had a much stronger rSDS-PrPSc oligomer-inducing activity
in cells, we expected that MR100 would trap infectivity
more efficiently than P30. To test this, we pre-incubated
22 L-infected brain homogenates with 1.5 mM MR100
(22 L +MR100), 150 μL PBS (22 L + PBS) or 150 μL
DMSO (22 L +DM) for 2 h before injection via stereotaxy
into the brains of healthy Swiss mice. Immunoblot analysis
of 22 L+ MR100 inocula confirmed the presence of rSDS-
PrPSc oligomers after MR100 treatment (data not shown).
Survival time of mice inoculated with 22 L +MR100 brain
homogenates (n = 8; red) was substantially increased
(non-parametric Mantel-Cox log-rank test, ** p = 0.007)
compared to animals inoculated with 22 L + PBS (black)
or 22 L + DM (blue) brain homogenates (n = 9 for both
groups)(Fig. 9a-b). Remarkably, in the group of mice inoc-
ulated with 22 L +MR100 brain homogenates, 50 % of an-
imals developed symptoms after an extended period of
incubation, whereas the other 50 % survived without
showing symptoms (Fig. 9a-b). The median survival time
of animals with prion-disease symptoms was 281 days for
mice injected with 22 L +MR100 brain homogenates,
199 days for the 22 L + PBS group and 191 days for the
22 L +DM group (Fig. 9b). High concentrations of MR100
can trap prion infectivity in the inoculum, increasing the
animals’ survival time by about 30 % for the subgroup that
develops the disease. Histopathological analyses were per-
formed to compare the brain tissues of animals that were
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injected with 22 L +MR100 inocula and did or did not
develop symptoms. Spongiosis and astrocytic gliosis
(assessed by GFAP expression) were detected in the brain
of mice with symptoms, but not in mice without symp-
toms that were sacrificed at 314 days post-inoculation
(d.p.i.) or non-inoculated control animals (Fig. 9c). In
addition, rPrPSc labeling was detected by PET-blot analysis
(Fig. 9d) with the SAF84 antibody in the brain of sick ani-
mals injected either with 22 L +DM or 22 L +MR100 in-
ocula and sacrificed with symptoms. However, no rPrPSc
labeling was present in non-inoculated healthy control an-
imals or mice inoculated with 22 L +MR100 killed at 314
d.p.i. without symptoms. Altogether, this data showed that
MR100 can trap prions in the inoculum and is even more
efficient than P30, because 50 % of animals were still alive
and asymptomatic at 315 d.p.i. [16].
Discussion
Due to the unique nature of prion agents and their
mode of propagation, PrPC and PrPSc (PrP27-30) are the
main targets in therapeutic and diagnostic approaches.
Most screening assays with prion-infected cells to
identify new anti-prion drugs have focused on reducing
the level of PrP(27-30). However, it is difficult to assess
which PrPSc species (small PrPSc oligomers, large aggre-
gates or amyloid fibrils) are targeted by a drug because,
after PK digestion and in SDS and reducing conditions,
all PrPSc species are dissociated, leading to a monomeric
band known as PrP(27-30). In addition, global decrease
of PrPSc levels in the cells is not always correlated with
diminished infectivity [21]. A second strategy is based
on the identification of small molecules that favor the
detection of PrP(27-30) oligomers (also called rSDS-PrPSc
oligomers) on western blot [16] as they could stabilize or
cross-link PrPSc species [16]. Although it seems contra-
dictory to promote the formation of such species, a recent
study showed that a novel oligomer modulator (Anle138b)
strongly reduced high molecular weight species and in-
creased the survival time of prion and Parkinson’s disease
mouse models [22]. Studies on Alzheimer’s disease have
shown that small molecules can be powerful tools for the
modulation of amyloid formation cascades and demon-
strated that acceleration of fibril formation reduces Aβ42
toxicity in human neuroblastoma cells and in rat brain
Fig. 8 RCA efficiently detects rSDS-PrPSc oligomers in patients with sporadic Creutzfeldt-Jakob disease (sCJD). a Freshly homogenized human
brain tissues from patients with sCJD (codon 129 Met/Met or Val/Val polymorphisms) were analyzed using RCA. The number on the figures
corresponds to the identification numbers attributed by the tissue bank. The brain homogenate from a healthy control (NBH, the same as in Fig. 7)
was used as negative control. 50 μL of 10 % human brain homogenates in 100 μL PBS/2 % Sarkosyl were incubated with 2 mM MR100 at room
temperature for 2 h and centrifuged at 11,000 g for 5 min. Supernatants (S) and pellets (P) were immunoblotted with the SAF mix. Molecular
masses (20–75 kDa) are indicated on the left side of the panels. b The table below shows: (i) the duration (in months) of the symptomatic phase
of the disease; (ii) the results of the densitometry analysis of oligomers after subtraction of the background to normalize each value (ImageJ software);
and (iii) the results of the densitometry analysis of the monomers in the pellet (P) and in the supernatant (S), and the calculated ratio (P/S) obtained for
each sample (Additional file 1: Table S1 for calculation of ratios). c The correlation between the oligomer amount and the duration of the symptomatic
phase of the disease in the 10 sCJD samples was assessed with the Pearson’s test using GraphPad (San Diego, CA, USA)
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slices [23, 24]. Altogether these studies on oligomer mod-
ulators demonstrate that small molecules can redistribute
the equilibrium between the various species of the amyl-
oid cascade in prionopathies and that these strategies
might be useful in identifying new compounds for diagno-
sis or therapeutic purposes.
Recently, we identified a family of thienyl pyrimidine
compounds that favor rSDS-PrPSc oligomers and dimin-
ish prion infectivity when mixed with the prion-infected
inoculum in bioassay studies [16]. In this work, we de-
signed and synthesized an analog, MR100, with stronger
rSDS-PrPSc oligomer-inducing activity to better under-
stand its mechanism of action and further evaluate the
diagnostic and therapeutic potentials of this family of
molecules. MR100 is effective at nanomolar concentra-
tions in N2a58/22 L cells and has a broad spectrum of
action as indicated by its rSDS-PrPSc oligomer-inducing
activity on rodent and human prion strains.
We used the fluorescence properties of MR100 to
study the interaction of the molecule with two forms of
the prion protein: either the soluble recPrP or the fibrillar
PrP. MR100 is a hydrophobic compound, and in an aque-
ous environment its fluorescence is quenched. Upon bind-
ing with recPrP or PrP fibrils, the environment of MR100
is less aqueous and we observed an increase of the fluores-
cence of MR100 molecule (signal intensity doubled). Fol-
lowing incubation of MR100 with PrP fibrils, we also
observed a strong red-shift of the emission spectrum from
Fig. 9 Pre-incubation of brain inoculum with MR100 substantially increases the survival time of injected animals. a Table with the number of
animals sacrificed with symptoms before 315 days post-inoculation compared to the total number of animals for each group. b Kaplan-Meier
survival plots of mice inoculated (15 μL/each mouse) with a 22 L-infected brain homogenate that was previously diluted in 2 % Sarkosyl/PBS and
incubated at a final concentration of 1.5 mM MR100 (n = 8; 22 L + MR100; red) or an equivalent volume of DMSO (150 μL) (n = 10; 22 L + DM;
blue) or PBS (150 μL) (n = 10; 22 L+ PBS; black) at room temperature for 2 h. c Histological analyses of thalamus (Th) sections from mice not inoculated
with prions (1), or that were inoculated with 22 L + DM inoculum (2) or 22 L +MR100 inoculum and presented no symptoms (3) or with symptoms (4)
of prion disease when they were killed (d.p.i., days post-inoculation). Tissue sections were stained with hematoxylin and eosin (HE) to confirm the prion
pathology as indicated by the presence of vacuoles and probed with anti-GFAP antibodies as a marker of astrocytic gliosis. Tissue labeling
was performed on several animals (2-3 per group) and images are representative of the staining observed in each group. d PET-blot analysis of frontal
tissue sections of mice non-inoculated with prions (1), or that were inoculated with 22 L + DM inoculum (2), or 22 L +MR100 inoculum and presented
no symptoms (3) or with symptoms (4) of prion disease when they were killed. The SAF84 antibody was used to detect rPrPSc proteins and the Vectastain
ABC-AmP Kit (Vector laboratories, USA) to reveal antibody binding. Scale bars, 10 μM, w: with, w.o.: without symptoms
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452 nm to 460 nm, and a large shoulder appeared around
500 nm, illustrating substantial modifications in the envir-
onment of MR100. These differences suggest that MR100
may have different properties towards PrP isoforms. In-
deed, SDS-PAGE gel experiments allowed us to directly
visualize the binding of MR100 on hamster PrP fibrils due
to the orange coloration of PrP bands with MR100, but also
with the formation of rSDS-oligomer species. Altogether,
these experiments indicate that MR100 compound inter-
acts with large aggregates of PrP and is able to cross-link
those species and form rSDS-oligomers in denaturing con-
ditions. Remarkably, MR100 presents some structural ana-
logies with a class of chemicals called the Luminescent
Conjugated Oligothiophene (LCOs) that were recently
shown to interact with a wide variety of amyloid fibrils and
protein aggregates such as amyloid-beta and tau [25, 26].
Thus, MR100 may also interact with other types of
amyloids in vitro.
We also evaluated the potential of MR100 as a diag-
nostic tool and we took advantage of the MR100 precipi-
tation effect to develop the “rapid centrifugation assay”
(RCA). This assay requires an incubation step with
MR100 at room temperature, followed by a quick centri-
fugation, without need for PK digestion. We show that
RCA can be used to differentiate 22 L- or 263 K-infected
from healthy rodent brain samples by detecting the pres-
ence of 50-75 kDa PrPSc oligomers in the pellet fraction.
Moreover, RCA allows the detection of traces of oligo-
mers in hamster brain samples as early as day 109 post-
infection, whereas following PK digestion no rPrPSc
signal is visible until a later stage. Altogether, these data
suggest that RCA could be used for the early detection
of prions in animal models.
Finally, we adapted the RCA method to detect PrPSc
oligomers in human brain homogenates. We show that
it can differentiate between samples from patients with
sCJD or vCJD and samples from healthy controls. More-
over, in samples from sCJD patients, the levels of PrPSc
oligomers in the pellet was positively correlated with
the duration of the symptomatic phase of the disease
(r2 = 0.78, *** p value = 0.0007). This is remarkable be-
cause it suggests a link between the amount of a prion
biomarker and the duration of the symptomatic phase of
the disease in the affected patient. In addition, the tissue
samples from patients with sCJD were cerebellar, a brain
area that was previously associated with variability in the
detection of prions by immunohistochemistry (IHC) in
comparison to the cortical regions (50-63 % of the cere-
bellum specimens were positive by IHC compared to cor-
tex) [11]. All the cerebellum samples tested by RCA were
found positive, suggesting that our assay is quite sensitive.
It will now be important to test samples from other brain
areas to better define the RCA sensitivity. Phosphotung-
stic acid precipitation (PTA) is another method based on
PrP precipitation that allows for better detection of prions
in samples [27]. However, in the PTA protocol the prote-
ase digestion step is needed to differentiate PrPC from
PrPSc isoforms, whereas with RCA protease digestion is
not required, allowing for detection of both sensitive and
resistant PrPSc species. Compared to the PTA, the RCA
method using MR100 is based on the detection of rSDS-
PrPSc oligomers, which is not the case for PTA, since olig-
omers are usually proteinase K digested. Similar to the
PTA, we noticed that MR100 is able to precipitate PrPC
but without forming rSDS-dimers/trimers of PrPC by
opposition to PrPSc, and this effect is highly efficient in ro-
dent strains (Figs. 7b and 8a). Our in vitro fluorescence
studies with MR100 suggested a difference in the inter-
action between PrP isoforms. Indeed, with MoPrP(23-230)
we observed an increase in the fluorescence of MR100,
suggesting an interaction. However, with PrP fibrils, the
fluorescence of MR100 is shifted from 452 nm to 460 nm
and a shoulder appears around 500 nm, showing a strong
modification in the environment of MR100 and suggesting
a possible interaction with quaternary structural elements
of PrP fibrils. MR100 is a highly hydrophobic compound
and one can imagine that MR100 interacts with hydro-
phobic structure elements of PrPSc, and is able to cross-
link fibrils (Fig. 2d).
Recently, a novel prion disease, without PRNP muta-
tions, was described by Gambetti [5]. This new disease,
named “variably protease-sensitive prionopathy” (VPSPr),
which represents 2-3 % of all CJD cases, is characterized
by the presence of an abnormal prion protein in the brain
that is highly sensitive to proteinase K. Indeed, examin-
ation of brain tissues from 26 patients showed that the
genotype at codon 129 (MM, MV or VV) influenced the
PK-resistance of PrPSc [5–8]. In addition, VPSPr cases do
not have mutations in the PRNP gene, thus they are
difficult to detect with classical assays. It would be of
particular interest to test brain tissues from patients with
VPSPr using the RCA to see whether PK-sensitive
oligomers can be detected.
Since MR100 is effective at nanomolar concentrations
in N2a58/22 L cells and has a broad spectrum of action,
as indicated by its rSDS-PrPSc oligomer-inducing activity
on rodent and human prion strains, we asked whether
this oligomeric activity induced by MR100 could have an
impact on prion infectivity. Pre-incubation of 22 L
prion-infected brain homogenates with an excess of
MR100 before inoculation into mouse brains substan-
tially increased the survival times of animals compared
to controls (p = 0.007) and, 50 % of animals survived
without succumbing to the disease. This result is in
agreement with our previous bioassay experiments ob-
tained with P30-treated inoculi showing a slight decrease
of the infectivity in mice [16]. Here, we showed that
MR100 is much more efficient than P30 at trapping
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prion infectivity, probably due to the substantial differ-
ence in their activity (ED50 is 17 μM for P30, and 1 nM
for MR100) [16]. As MR100 exhibits a strong ability to
precipitate PrP isoforms compared to P30, we hypothe-
sized that an excess of MR100 could form a protective
shell around PrP species, which then aggregate and par-
tially inactivate the prion strain, blocking pathways of
prion replication. A direct application of this property
might be the use of MR100 as a surface prion decontami-
nant. Interestingly, a recent paper published by Herrmann
et al., [28] showed that administration of polythiophenes
(compound structurally similar to MR100) to the brain of
prion-infected mice via osmotic minipumps, led to a sur-
vival extension of 80 % and demonstrated activity against
both mouse and hamster prions. Due to the similarity in
chemical structure between MR100 and these oligothio-
phenes, and because oligothiophenes have the ability to
generate SDS-stable PrPSc oligomers such as for MR100,
we expect that treatment with MR100 using a protocol
with osmotic minipump may lead to an increase of the
survival life of prion-infected animals.
Conclusion
To conclude, MR100 is a promising tool for studying
the mechanism of prion propagation and has allowed
the development of an alternative method for the identi-
fication of prion-infected brain samples based on the
rSDS-PrPSc oligomers that could be useful for specific
purposes. We are now testing whether this assay can be
adapted for biological fluids, especially blood. Regarding
our bioassay results, we will further explore the potential
of MR100 as a prion decontaminant.
Methods
Ethics statement
This project follows the specific French national guide-
lines on animal experimentation and animal well-being
and was approved by the Ethic Committee for Animal
Experimentation (“Effet des dérivés thiényls pyrimidi-
ques sur le mécanisme de réplication des prions”, Nr.
CE-LR-11001).
Tissue samples from individuals with CJD and controls
were from: (i) the collection of the brain bank of the
Institute of Neurology of the Medical University of
Vienna. Samples were collected following local regulations
for diagnostic purposes in the frame of CJD Surveillance.
Anonymized tissue samples remaining after diagnosis were
used in this project in the framework of the “Molecular
neuropathologic investigation of neurodegenerative dis-
eases” study that was approved by the Ethical Committee
of the Medical University of Vienna (Nr. 396/2011), and
followed the principles of the Helsinki declaration; (ii) the
collection of the CJD Resource Center, National Institute
for Biological Standards and Control (NIBSC, UK) covered
by the National Research Ethics Service (NHS, UK) with
the REC ref number 09/H0405/2. Samples provided by
NIBSC were anonymized.
Human samples
Brain samples (10 % (w/v) homogenate in 0.25 M sucrose/
PBS) from patients with new variant CJD (vCDJ) (NHBY0/
0003 and NHBY0/0014) were provided by the National In-
stitute for Biological Standards and Control (NIBSC, UK,
www.nibsc.ac.uk). A normal human brain sample (NHBZ0/
0005) and a sample from a patient with sporadic CJD
(sCDJ) (codon 129 Met/Met polymorphism) (NHBX0/
0001) were also provided as controls. Frozen cerebellum
specimens from five patients with sCJD of Type 1 (codon
129 Met/Met polymorphism) and from five patients with
sCJD of Type 2 (codon 129 Val/Val polymorphism) were
provided by Dr. Kovacs (Institute of Neurology, Vienna).
Biological reagents and antibodies
Pefabloc and proteinase K were purchased from Roche
Diagnostics (Mannheim, Germany). The protein assay kit
based on the bicinchoninic acid (BCA) was purchased from
Pierce (Thermofisher Scientific, Saint Herblain, France).
For immunoblotting analyses, we used a mix (SAF mix) of
three anti-PrP antibodies (SAF60, SAF69 and SAF70) that
were kindly provided by Dr. Jacques Grassi (CEA, Saclay,
France). The SAF69 antibody is critical for detection of PrP
oligomers. The SAF84 antibody used for pet-blot analyses
were purchased from SpiBio (Montigny-le-Bretonneux,
France). Secondary antibodies were from Jackson Immu-
noResearch (West Grove, PA, USA). All other chemicals
and antibodies were purchased from Sigma (Paris, France).
Chemical reagents
The thienyl pyrimidine compounds A6, A12, A13, A14,
A17 and A18 that have rSDS-PrPSc oligomer-inducing ac-
tivity [16] were purchased from Maybridge (Cornwall,
United Kingdom) and Key Organics Limited (Cornwall,
United Kingdom). Stock solutions were prepared at 5 mM
and drugs were solubilized in DMSO according to the
suppliers’ recommendations. For the synthesis of MR1
(6-(thiophen-2-yl)-1,3,5-triazine-2,4-diamine), MR2 (6-
(5-bromothiophen-2-yl)-1,3,5-triazine-2,4-diamine), MR3
(5,5'-bistrimethyltin-2,2'-bithiophene) and MR100 (6,6'-
(2,2′:5′,2′′:5′′,2′′′-quaterthiophene-5,5'''-diyl)bis(1,3,5-
triazine-2,4-diamine)), reactions were carried out using
dried or freshly distilled solvents, under a dry argon at-
mosphere and according to the Stille cross-coupling path-
way described recently [18]. Elemental analyses were
performed by the "Service Central d’Analyse du CNRS
(Solaize, France)". 1H NMR spectra were recorded at
300.75 MHz, and 13C{1H} NMR spectra at 75.30 MHz
using a Bruker AV-300 instrument. Chemical shifts (δ)
were related to the residual solvent peak as internal
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standard. δ and coupling constant values (J) were expressed
in ppm and Hz, respectively.
Cell culture
The mouse neuroblastoma cell line N2a was purchased
from the American Type Culture Collection (ATCC
CCL131). The N2a58 subclone, which over-expresses
mouse PrP (MoPrP), was chronically infected with the
mouse-adapted scrapie strain 22 L (N2a58/22 L cells), as
described by Nishida [29]. N2a58 and N2a58/22 L cells
were cultured as described previously [16].
Cell screening assay, dose-response curves and
immunoblotting
Drug screening using N2a58 or prion-infected N2a58/
22 L cells was performed as previously described [16].
Briefly, 106 cells/25-cm2 flasks were incubated with
20 μM of each compound (final concentration) for
4 days. At confluence, cells were lysed in 400 μl lysis
buffer (0.5 % NP-40, 0.5 % Deoxycholate, 10 mM Tris-
HCl pH 8, 100 mM NaCl) and protein concentration
was measured using the BCA assay. For western blots,
all samples were normalized regarding their protein
amount and volumes. For the dose-response curve
(Fig. 1d), aliquots of 20 μL were taken as protein loading
controls probed with glyceraldehyde-3-P dehydrogenase
(G3PDH) or β-actin. Then, normalized samples were
digested with 20 μg/ml PK at a ratio of 1:25 (protease to
protein) at 37 °C for 1 h. Digestion was stopped with
1 mM Pefabloc and samples were centrifuged at 20 000 g
at 4 °C for 30 min. Pellets were dissolved in 20 μl lysis buf-
fer and 20 μl 2x loading buffer (0.1 M DTT, 3 % SDS, 20 %
glycerol, 0.4 M Tris-HCl pH 7.4 and bromophenol blue),
then boiled for 3 min before loading on 12 % SDS-PAGE
Criterion precast gels (Biorad). Western blotting was per-
formed according to standard procedures and MoPrP was
detected with the SAF mix, as previously described [30].
For the dose-response curves, about 1×106 N2a58/22 L
cells were plated in 25-cm2 flasks and incubated with
P30, A6 or MR100 at various concentrations (from
pM to μM) for 4 days. At confluence, cells were
lysed, extracts were normalized for protein amounts
and PK-digested as described above. Samples were
analyzed by western blotting using the SAF mix, as
described previously [30].
Purification of prion protein and formation of amyloid fibrils
Full-length recombinant mouse PrP encompassing resi-
dues 23-230 (MoPrP23-230) was expressed in E. coli and
purified as described previously [31]. The purified re-
combinant MoPrP23-230 was confirmed by SDS-PAGE
and electrospray mass spectrometry to be a single spe-
cies with an intact disulfide bond and correct molecular
weight as previously described in Ayrolles-Torro et al.,
[16]. After purification, MoPrP was stored in lyophilized
form at -20 °C until use.
Amyloid fibrils using full-length MoPrP23-230 were
formed using the manual setup protocol of Breydo et al.
[32], and fibril formation was monitored by collecting
aliquots to which 10 μM of thioflavin T were added as
described previously. The quality of freshly made fibrils
was also confirmed by transmission electron microscopy
as described previously [33]. Two amyloid strains: ham-
ster S-fibrils (for “shaking”) and hamster R-fibrils (for
“rotation”) were kindly provided by Dr. Ilia Baskakov.
Hamster fibrils were produced in vitro using full-length
hamster PrP, according to the manual format protocol as
described by Makarava and Baskakov [19].
Absorption spectroscopy of MR100 compounds and
fluorescence interaction studies
Five millimolar stock solution of MR100 compound was
diluted at a final concentration of 5 μM, in 50 mM MES
buffer pH 5, 1 % DMSO. Absorption spectra were recorded
from 200-600 nm using a spectrophotometer Specord 250
(Analytikjena, France) and MR100 compound exhibits
a maximal absorption wavelength at 470 nm (λmax).
This wavelength (λmax = 470 nm) was selected for excita-
tion of MR100 molecule using a fluorimeter FluoroMax2
(JobinYvon Spex, Tokyo, Japan). Lyophylized MoPrP(23-
230) was solubilized at 0.5 mg/mL (0.2 mM) in 50 mM
MES buffer pH 6, and filtrated on 0.2 μm filter. Then,
Mo(PrP23-230) stock solution was diluted in 50 mM MES
buffer at a final protein concentration of 4.4 μM, and
mixed with 50 μM of MR100 compound, 1 % DMSO, dur-
ing 2 h at 25 °C. Fluorescence experiments were conducted
by excitation of the MR100 compound and emission spec-
tra were recorded by excitating at 470 nm. Alternatively,
MoPrP(23-230) at 0.5 mg/mL was mixed with 50 μM of
MR100 (diluted in 50 mM MES buffer pH 5, 1 % DMSO)
and incubated for 2 h at 37 °C. Fluorescence analyses of
tryptophan and tyrosine residues of PrP were performed
by excitation of samples at 295 nm. Emission spectra be-
tween 300 and 400 nm were recorded by exciting the fluor-
escence at 295 nm before the incubation of PrP with
MR100 (T0) and after 2 h of incubation (T120).
SDS-PAGE gel electrophoresis interaction studies
Hamster S- or R-fibrils (4.4 μM) were incubated with
40 μM of P30, A6 or MR100 compounds diluted in
50 mM MES buffer, 1 % DMSO, during 2 h at room
temperature. Samples were mixed with 4X Loading buf-
fer, boiled 15 min at 90 °C, and loaded on SDS-PAGE
gel 12 %. Proteins in gel were revealed by silver staining.
Aggregation assay using brain homogenates
Brain tissues from terminally sick mice (infected with 22 L
prions) and hamsters at various stages of disease (infected
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with the 263 K strain) were homogenized in 10 % (w/v)
PBS using microbead-containing tubes and a Ribolysor ap-
paratus (Biorad, Marnes la Coquette, France). Samples were
shaken for 45 s and then homogenates were collected with
an insulin syringe to obtain a homogeneous suspension.
Protein concentration was measured using the BCA assay
and samples were normalized in order to get equivalent
amounts of proteins and volumes. Before incubation of
samples with compound MR100 and/or proteinase K,
20 μL of the normalized aliquots were collected as loading
controls probed with β-actin.
To determine MR100 oligomer-inducing activity in
brain homogenates, 50 μL of infected brain extracts
(10 % w/v) were diluted in PBS/2 % Sarkosyl and incu-
bated with 1 mM MR100 or DMSO (control) in a final
volume of 0.5 mL for 1 h. Rodent samples were then
PK-digested according to the previously described proto-
col [16]. For human samples, various PK concentrations
were tested and an appropriate signal on western blot
was obtained after digestion with 125 μg/ml PK at 37 °C
for 1 h. Fifty microliters of each sample were mixed with
an equal volume of 2x loading buffer and boiled for
3 min. Thirty microliters were loaded onto 12 % SDS-
PAGE gels and analyzed by western blotting as described
above using the SAF mix.
Rapid Centrifugation Assay (RCA)
Fifty microliters of 10 % (w/v) rodent brain homogenates
(22 L- or 263 K-infected and non-infected) were diluted
in 300 μL 2 % Sarkosyl/PBS and incubated with 150 μL
DMSO or P30 or MR100 at a final concentration of
1.5 mM at room temperature for 1 h. Samples were then
centrifuged in a benchtop centrifuge (Eppendorf ) at
8000 g for 5 min. Supernatants were removed and 30 μL
aliquots were mixed with an equal volume of 2x loading
buffer. Pellets were suspended in 30 μL 2 % Sarkosyl/
PBS and mixed with an equal volume of 2x loading buf-
fer. Supernatants and pellets were analyzed by western
blotting using the SAF mix. For human samples (vCJD,
sCJD and negative controls), 50 μL of 10 % (w/v) brain
homogenates were diluted in 100 μL 2 % Sarkosyl/PBS
and incubated with 100 μL MR100 at a final concentration
of 2 mM at room temperature for 2 h. Samples were then
centrifuged in a benchtop centrifuge (Eppendorf) at 11
000 g for 5 min. Pellets and supernatants were then proc-
essed like for the rodent samples.
Bioassay using 22 L-infected brain homogenates treated
with MR100
We incubated 50 μL of a 10 % solution (w/v) of
22 L-infected brain homogenates in PBS with 2 %
Sarkosyl (300 μL) and 1.5 mM MR100 (150 μL) or
150 μL DMSO (DM) or PBS as controls, at 20 °C for 2 h.
To determine prion infectivity, samples were diluted (105
times) with normal brain homogenates before intracere-
bral inoculation as described previously [16]. Fifteen mi-
croliters of MR100-treated (n = 8), DMSO-treated (n = 10)
or PBS-treated samples (n = 10) were injected into the lat-
eral ventricle of Swiss mice using a stereotaxic frame (Kopf
Instruments, Tujunga, CA, USA) with coordinates as fol-
lows: L: 1.0 mm; R: 0 mm; and P: -3.0 mm [34]. Groups of
five mice were housed in cages placed in a ventilated pro-
tective cabinet. Mice were scored positive for prion disease
when three signs of neurologic dysfunction were observed
and when progressive deterioration (according to 16 diag-
nostic criteria) was apparent, as described previously [35,
36]. Once clinical signs were detected, animals were ob-
served daily and killed in extremis. Their brain was re-
moved and immediately frozen at –80 °C or fixed in
AntigenFix (Diapath, France) for immunohistochemi-
cal analysis.
Immunohistochemistry
Brain tissues were fixed in AntigenFix solution (Diapath,
France) for 24 h. Then, they were decontaminated for
30 min in formic acid solution according to the protocol
described by Andréoletti et al. [37] and stored in
100 mM phosphate buffer at pH 7.4 with 0.02 % sodium
azide. Samples were dehydrated in graded ethanol,
cleared in cedar oil and embedded in paraffin. Frontal
6- to 10-μm sections were cut using a microtome and
mounted on Superfrost Plus slides (Microm France,
Francheville). Sections were dewaxed and stained with
hematoxylin and eosin as described previously [38].
Immunolabeling with anti-GFAP antibodies was per-
formed according to the instructions provided with the
Strept ABC Complex Kit. Labeling was visualized using 3-
3’-diaminobenzidine chromogen solution (Sigma, France).
For paraffin-embedded tissue blots (PET-blots), 6 μm
frontal sections were cut using a microtome and placed
on nitrocellulose membrane. After drying at 50 °C for
48 h, sections were dewaxed, digested with 25 μg/mL PK
at 56 °C overnight and then denatured with 3 M guanidine
thiocyanate for 10 min. Membranes were blocked with
casein for 30 min. The SAF84 antibody was used to label
rPrPSc and the Vectastain ABC-AmP kit (Vector labora-
tories, USA) to reveal antibody binding.
Software and statistical analysis
ImageJ (http://rsb.info.nih.gov/ij/index.html) was used to
compare the intensity of individual western blot bands.
It uses a graphical method that generates lane profile
plots by drawing lines to enclose the peaks of interest
and then measuring the peak area using the wand tool.
For each band, we obtained values corresponding to the
defined area.
Correlations between the duration of the disease symp-
tomatic phase and the oligomer amounts were calculated
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using the GraphPad software (San Diego, CA, USA) and
Pearson’s test. Correlations were considered significant at
p ≤ 0.05. Kaplan-Meier survival curves were created using
the GraphPad software and the difference between curves
was tested using the non-parametric Mantel-Cox test,
with a probability of 0.05 defined as significant difference.
Additional file
Additional file 1: Table S1. Densitometry analysis of monomers in the
pellet (P) and in the supernatant (S) fractions to determine ratios (P/S).
(PDF 54 kb)
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